Follow us on Twitter
twitter icon@FreshPatents


Cancer patents

      

This page is updated frequently with new Cancer-related patent applications.

SALE: 200+ Cancer-related patent PDFs



 Neoantigen identification, manufacture, and use patent thumbnailNeoantigen identification, manufacture, and use
Disclosed herein is a system and methods for determining the alleles, neoantigens, and vaccine composition as determined on the basis of an individual's tumor mutations. Also disclosed are systems and methods for obtaining high quality sequencing data from a tumor.
Gritstone Oncology, Inc.


 Biomarkers patent thumbnailBiomarkers
The invention provides a method for screening for colorectal cancer, the method comprising: screening a biological sample from an individual for one or more biomarkers selected from the group defined in table 1 and/or table 6, wherein the presence of or increased expression of the one or more biomarkers relative to a control sample is indicative that the individual is at risk of suffering from or is suffering from colorectal cancer. The invention also provides an array and kit suitable for use in the methods of the invention, methods of treating colorectal cancer and therapeutic agents for use in methods of treating cancer..
Stichting Vu-vumc


 Use of phosphatidylinositol phosphate-binding material for apoptosis detection patent thumbnailUse of phosphatidylinositol phosphate-binding material for apoptosis detection
The present invention relates to a method for detecting apoptosis using a phosphatidylinositol phosphate-binding material, a method for screening anticancer agents, a method for screening apoptosis-inhibiting materials, and a method for inhibiting phagocytosis.. .
Gachon University Of Industry-academic Cooperation Foundation


 Prostate cancer screening module and  operating the same patent thumbnailProstate cancer screening module and operating the same
The present invention relates to a prostate screening module and the method for operating the same. It uses nanometer-grade nickel oxide as the screening film.
Chang Gung University


 Methods and compositions for treatment or diagnosis of cancers related to gabra3 patent thumbnailMethods and compositions for treatment or diagnosis of cancers related to gabra3
Compositions and methods for diagnosing and treating breast cancer, including metastatic breast cancer, are provided. In one aspect, a diagnostic composition comprising a reagent which is capable of specifically complexing with, or identifying, gabra3 is provided.
The Wistar Institute Of Anatomy And Biology


 Methods of glucocorticoid therapy and determining responsiveness thereof patent thumbnailMethods of glucocorticoid therapy and determining responsiveness thereof
The invention provides one or more mirnas, including but not limited mir-103, mir-30d, and mir-30e, for predicting the response of cancer cells to glucorticoids treatment. The invention further provides therapeutic uses of said mirna molecules for increasing cells sensitivity to glucorticoids induced cell apoptosis..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.


 Kras mutations and resistance to anti-egfr treatment patent thumbnailKras mutations and resistance to anti-egfr treatment
The disclosure provides compositions and methods for detecting and predicting acquired resistance to anti-egfr treatment in colorectal cancers. Also provided are compositions and methods of preventing, reversing or delaying the acquired resistance.
Memorial Sloan- Kettering Cancer Institute


 Methods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer patent thumbnailMethods of diagnosing or treating prostate cancer using the erg gene, alone or in combination with other over or under expressed genes in prostate cancer
The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


 Methods and compositions for modulating lung cancer tumor initiating cells (tic), and oxytocin receptor (oxtr) modulatory agents for use in practicing the same patent thumbnailMethods and compositions for modulating lung cancer tumor initiating cells (tic), and oxytocin receptor (oxtr) modulatory agents for use in practicing the same
Methods of modulating lung cancer, e.g., squamous cell carcinoma (sqcc), tumor initiating cells (tic) are provided. Aspects of the methods including contacting a tic with an oxtr modulatory agent, e.g., an inhibitory agent, in a manner sufficient to modulate the tic.
The Board Of Trustees Of The Leland Stanford Junior University


 Composition for treating cancer associated with hpv infection patent thumbnailComposition for treating cancer associated with hpv infection
The present invention relates to a composition for preventing or treating diseases associated with human papillomavirus (hpv), and more specifically, cancer associated with hpv, and even more specifically, cervical cancer. The nucleotide sequence of the present invention, the sequence in which the base thereof is modified, and a specific combination thereof can be useful in a composition for effectively treating diseases associated with hpv infection by greatly inhibiting the expression of the e6/e7 gene of hpv type 16 or 18..
Abion Inc.


Targeting human satellite ii (hsatii)

Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite ii (hsatii) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic hsatii satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3d culture.
The General Hospital Corporation

Single cell-derived organoids

The present invention relates to organoids derived from a single cell, such as a prostate cancer cell, and methods and compositions relating to the production and use thereof, including cell culture medium for producing organoids and methods of personalized treatment for prostate cancer. The invention further provides a humanized mouse comprising a prostate organoid derived from a patient's prostate cell..
Rutgers, The State University Of New Jersey

Anti-muc1 antibody or antigen-binding fragment thereof and uses thereof

The present invention provides: an antibody exhibiting specificity for muc1, the antibody having a glycan structure expressed at high levels in cancer cells; a method for manufacturing this antibody; and a novel means and method for the diagnosis and prevention and/or treatment of cancer using this antibody. The present invention is a monoclonal antibody to human muc1, wherein the antibody specifically recognizes a glycopeptide having a human muc1 tandem unit and furthermore having an o-linked glycan core (0(tn)) in any one of the threonine and serine in the amino acid sequence of this human muc1 tandem unit.
Medicinal Chemistry Pharmaceuticals, Co., Ltd.

Methods for treating cancer

The present invention provides methods of treating cancer, particularly cancers that had developed resistance to pd-1 and pdl-1 blockade. Also included are methods of identifying therapeutic targets for the treatment of cancer..
Dana-farber Cancer Institute, Inc.

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-lung cancer agent by utilizing the platform technology for macromolecule intracellular transduction..
Cellivery Therapeutics, Inc.

Gold(i) complexes with anticancer properties and methods of use thereof

Monomeric and dimeric gold(i) complexes as anticancer agents. The gold(i) complexes are coordinated to mixed ligands: one phosphine-based ligand that may be monodentate or bidentate and at least one dithiocarbamate-based ligand that is monodentate.
King Fahd University Of Petroleum And Minerals

Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, the production and use thereof

In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.. .
Sanochemia Pharmazeutika Ag

Recombinant t cell receptor ligand compositions and methods for treatment of prostate cancer

Disclosed herein are compositions and methods for treating or inhibiting prostate cancer. The compositions include a mhc molecule including covalently linked first and second domains, wherein the first domain is an mhc class ii β1 domain and the second domain is an mhc class ii α1 domain, wherein the amino terminus of the α1 domain is covalently linked to the carboxy terminus of the β1 domain, and a prostate specific antigen peptide covalently linked to the first domain.
University Of Maryland, Baltimore

Kif20a epitope peptides for th1 cells and vaccines containing the same

Isolated kif20a-derived epitope peptides having th1 cell inducibility are disclosed herein. Such peptides can be recognized by mhc class ii molecules and induce th1 cells.
Oncotherapy Science, Inc.

Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector

Compositions and methods are provided herein for improved dual immunization strategies that induce in a subject a robust immune response. The methods described are therefore useful for treating and/or preventing (i.e., reducing the likelihood or risk of occurrence) different diseases, disorders, and conditions such as cancers and infectious diseases for which induction of a humoral immune response and/or cellular immune response is desired and beneficial..
Immune Design Corp.

Antitumor activity of multi-kinase inhibitors in triple negative breast cancer

B) at least one chemotherapeutic agent, suitable for use in the treatment of breast cancer.. .

Oxathiazine derivatives as antibacterial and anticancer agents

New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed..
Geistlich Pharma Ag

Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers

A therapeutic nanoparticle comprising: at least one oncologic drug; and taurolidine, whereby to provide the simultaneous delivery of the at least one oncologic drug and taurolidine, thereby harnessing the synergistic effect of taurolidine on the at least one oncologic drug.. .
Cormedix Inc.

Methods for treating her2-positive breast cancer

Methods of treating breast cancer are provided where a quantitative her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific her2 fragment peptide is precisely quantitated by srm-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the her2 protein..
Expression Pathology, Inc.

Methods and compositions for treatment of her-positive cancers

Cancers that overexpress tyrosine kinase receptors of her family are treated with drugs acting on these receptors. Although her-targeting drugs have revolutionized the treatment of her-positive cancers, high rates of primary and treatment-emergent resistance limit their clinical utility.
University Of South Carolina

Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer

A treatment of patients afflicted with prostate cancer, wherein the treatment includes administering to a mammal in need thereof at least one tyrosine kinase inhibitor or mast cell inhibitor that is an inhibitor of kinase activity selected from the tyrosine kinases of: c-kit, pdgfr, lyn, fyn, or any combination thereof, in particular masitinib, optionally in combination with at least one pharmaceutically active ingredient.. .
Ab Science

Methods and compositions for determining resistance to androgen receptor therapy

Described herein are modified androgen receptor polypeptides that are resistant to inhibition by an androgen receptor inhibitor. Described herein are compositions, combinations, and kits containing the modified androgen receptor polypeptides and methods of using the modified androgen receptor polypeptides.
Aragon Pharmaceuticals, Inc.

Lung cancer adjuvant therapy

The present invention includes compositions and methods for the treatment of cancer comprising an antineoplastic drug and an inhibitor of chromosome maintenance region 1 (crm1) protein expression or activity, wherein the inhibitor of crm1 enhances the anti-neoplastic effect of the antineoplastic drug.. .
Texas Tech University System

Treatment for tumors driven by metabolic dysfunction

The present disclosure relates to modified or polymer conjugated metap2 inhibitors. The present disclosure also relates to methods of treating metabolically-driven diseases and disorders, such as certain cancers..
Syndevrx, Inc.

Prediction of recurrence of non-small cell lung cancer with tumor infiltrating lymphocyte (til) graphs

Methods and apparatus predict non-small cell lung cancer (nsclc) recurrence using radiomic features extracted from digitized hematoxylin and eosin (h&e) stained slides of a region of tissue demonstrating nsclc. One example apparatus includes an image acquisition circuit that acquires an image of a region of tissue demonstrating nsclc, a segmentation circuit that segments a cellular nucleus from the image, a feature extraction circuit that extracts a set of features from the image, a tumor infiltrating lymphocyte (til) identification circuit that classifies the segmented nucleus as a til or non-til, a graphing circuit that constructs a til graph and computes a set of til graph statistical features, and a classification circuit that computes a probability that the region will experience nsclc recurrence.
Case Western Reserve University

Prediction of recurrence of non-small cell lung cancer

Methods, apparatus, and other embodiments associated with predicting non-small cell lung cancer (nsclc) patient response to adjuvant chemotherapy therapy using radiomic features extracted from digitized hematoxylin and eosin (h&e) stained slides of a region of tissue demonstrating nsclc. One example apparatus includes an image acquisition circuit that acquires an h&e image of a region of tissue demonstrating nsclc pathology, a segmentation circuit that segments a region of interest (roi) from the diagnostic radiological image, a feature extraction that extracts a set of discriminative features from the roi, and a classification circuit that generates a probability that the roi will experience nsclc recurrence.
Case Western Reserve University

Methods and arrays for use in the same

The present invention provides a method for diagnosing breast cancer comprising or consisting of the steps of (a) providing a sample to be tested; and (b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of one or more biomarker selected from the group defined in table a(i) and/or table a(ii); wherein the presence and/or amount in the test sample of the one or more biomarker selected from the group defined in table a(i) and/or table a(ii) is indicative of the presence of breast cancer cells in the individual, corresponding uses, methods of treating breast cancer, together with arrays and kits for use in the same.. .
Immunovia Ab

Method of screening cancer cells using wrinkle patterns on a thin membrane

Systems and methods for performing cancer screening assays are disclosed. The disclosed systems and methods use a thin film comprising cross-linked polysiloxane.
Arizona Board Of Regents On Behalf Of Arizona State University

Methylated markers for colorectal cancer

Disclosed herein is a combination of genomic sequences whose methylation patterns have utility for the improved detection and differentiation between colorectal neoplasms. Further disclosed herein are methods, nucleic acids and kits for detecting or differentiating between colorectal neoplasms..
Clinical Genomics Pty Ltd

Sequence variants associated with prostate specific antigen levels

Certain sequence variants have been found to be useful for correcting prostate specific antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer..
Decode Genetics Ehf

Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer

A system for expression-based discrimination of distinct clinical disease states in prostate cancer is provided that is based on the identification of sets of gene transcripts, which are characterized in that changes in expression of each gene transcript within a set of gene transcripts can be correlated with recurrent or non-recurrent prostate cancer. The prostate cancer prognostic system provides for sets of “prostate cancer prognostic” target sequences and further provides for combinations of polynucleotide probes and primers derived there from.
Genomedx Biosciences, Inc.

Non-invasive gene mutation detection in lung cancer patients

A system and method for the detection of saliva biomarkers in bodily fluids is described. In particular, the system is suitable for detecting biomarkers of lung cancer in a subject.
The Regents Of The University Of California

Rna editing biomarkers for diagnosis, pharmacological screening and prognostication in cancer

Compositions and methods for expanding cd34+ cells, performing research related to cancer stem cells, rna-editing enzymes and for monitoring, diagnosing and treating, ameliorating and preventing diseases such as cancers or inflammatory diseases.. .
Regents Of The University Of California

A method to up-regulate cancer stem cell markers for the generation of antigen specific cytotoxic effector t cells

The invention concerns a method of preparing a composition comprising stimulated immune system cells such as dendritic cells (dc) for use in inducing immune response of cytotoxic t lymphocytes against colorectal cancer. The dendritic cells are pulsed by contact with colorectal cancer stem cells (csc) or their fragments thereof.
Tessa Therapeutics Pte. Ltd.

Carbonate polymer containing a functional group of disulfide five-membered ring in the side chain and application thereof

Apparatus relates to a carbonate polymer containing a functional group of disulfide five-membered ring in the side chain and application thereof. The polymer can be prepared from cyclic carbonate monomer containing a disulfide five-membered ring functional group through the activity controllable ring-opening polymerization.
Brightgene Bio-medical Technology Co., Ltd

Cell-permeable (icp)-socs3 recombinant protein and uses thereof

The present invention relates to providing improved cell-permeable (icp)-socs3 recombinant protein and uses thereof. Preferably, the icp-socs3 recombinant protein may be used as protein-based anti-pancreatic cancer agent by utilizing the platform technology for macromolecule intracellular transduction..
Cellivery Therapeutics, Inc.

Emetine derivatives, prodrugs containing same, and methods of treating conditions using same

Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the n2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment.

Dna oxidative damage repairing device and application method thereof

Disclosed are a dna oxidative damage repairing device and an application method thereof. The device is composed of an electrons emitting assembly, an electrons emitting electrode, a control system, a power source, a support and the like.

Suppression of myeloid derived suppressor cells and immune checkpoint blockade

Impressive responses have been observed in patients treated with checkpoint inhibitory anti-pd-1 or anti-ctla-4 antibodies. However, immunotherapy against poorly immunogenic cancers remains a challenge.
The Johns Hopkins University

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against various cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Composition containing neuropeptide y for inhibiting side effects of anticancer agents

Provided is a composition containing neuropeptide y for inhibiting side effects of anticancer agents. The neuropeptide y of the present invention exhibits an effect of mitigating side effects, especially bone marrow injury and neurological disorders, occurring due to the administration of anticancer agents, and thus may be useful as an anticancer adjuvant which may mitigate side effects of anticancer agents and enhance the effect of anticancer agents..
Kyungpook National University Industry-academic Cooperation Foundation

Di- and tri-cationic glycosylated antitumor ether lipids, l-gucosylated gaels and rhamnose-linked gaels as cytotoxic agents against epithelial cancer cells and cancer stem cells

Glycosylated antitumor ether lipids (gaels) kill cancer cells by a nonapoptotic pathway which is an attractive strategy to avoid resistance. To further optimize the antitumor effect, we prepared various analogs of di-, and tri-cationic gael analogs differing in the nature of the sugar (d-giucose or l-glucose), the anomeric linkage as well as position of the glycerolipid moiety.
The University Of Manitoba

Anticancer agents of the anthracyclin family

Are disclosed. In these compounds r1 is methyl, acetyl or hydroxyacetyl; r2-r5 and r10-r13 are independently h or methyl; r6 r7 and r8 are independently h, oh or och3; and n is zero or one.

Cancer drug and uses

A pharmaceutical composition comprising a cancer therapeutic that is capable of inhibiting and/or reducing the ability of a cancer cell to take up and utilize glucose or other energy source, a lipid or other building block of a cell membrane or organelle, and/or cholesterol. The pharmaceutical composition can comprise one or more cancer therapeutics that can be administered individually or in combination to an individual..
Health Clinics Limited

Compositions and methods for suppressing endometrial proliferation

The subject matter of the instant invention is pertinent to the field of hormone therapy. More specifically, the subject matter of the instant invention concerns methods of treating estrogen-dependent conditions such as endometrial hyperplasia and endometrial cancer in a female undergoing estrogen and/or selective estrogen receptor modulator (serm) therapy.
Repros Therapeutics Inc.

Pharmaceutical composition for treating prostate cancer

The present invention provides a pharmaceutical composition for treating prostate cancer in a subject in need thereof, which comprises a first agent comprising at least a anctin k (ank); and a second agent comprising at least an antroquinonol b (anqb); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of prostate cancer or to prevent or to reduce the risk of a prostate cancer metastasizing, compared to administration of the first agent or the second agent alone.. .
Ma Shen Kai Ruei Co., Ltd.

Pharmaceutical composition for treating lung cancer

The present invention provides a pharmaceutical composition for treating lung cancer in a subject in need thereof, which comprises a first agent comprising at least a dehydroeburicoic acid (deea); and a second agent comprising at least an anctin k(ank); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of lung cancer or to prevent or to reduce the risk of a lung cancer metastasizing, compared to administration of the first agent or the second agent alone.. .
Ma Shen Kai Ruei Co., Ltd.

Pharmaceutical composition for treating colorectal cancer

The present invention provides a pharmaceutical composition for treating colorectal cancer in a subject in need thereof, which comprises a first agent comprising at least a zhankuic acid d (zhad); and a second agent comprising at least an antroquinonol b (anqb); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of colorectal cancer or to prevent or to reduce the risk of a colorectal cancer metastasizing, compared to administration of the first agent or the second agent alone.. .
Ma Shen Kai Ruei Co., Ltd.

Pharmaceutical composition for treating breast cancer

The present invention provides a pharmaceutical composition for treating breast cancer in a subject in need thereof, which comprises a first agent comprising at least a dehydroeburicoic acid (deea); and a second agent comprising at least an antroquinonol b (anqb); as well as each of them can be obtained from the extractions of a fruiting body or a mycelium of antrodia camphorata wherein the first agent and the second agent shows synergistic effect for use in the treatment of breast cancer or to prevent or to reduce the risk of a breast cancer metastasizing, compared to administration of the first agent or the second agent alone.. .
Ma Shen Kai Ruei Co., Ltd.

Bruton's tyrosine kinase as anti-cancer drug target

Receptor protein kinases (rptks) transmit extracellular signals across the plasma membrane to cytosolic proteins, stimulating formation of complexes that regulate key cellular functions. Over half of the known tyrosine kinases are implicated in human cancers and are therefore highly promising drug targets.
The Research Foundation For The State University Of New York

Protein kinase c inhibitor for treating triple-negative breast cancer

Protein kinase c plays important roles in tnbc development and could be a specific target. The in vitro anti-proliferative activity of pkc inhibitor chelerythrine on a panel of breast cancer cell lines was evaluated.
Macau University Of Science Ang Technology

Compounds for treating brain cancer

For use in the treatment of a brain cancer selected from a mgmt positive astrocytic brain tumor, a metastatic brain cancer and primary cns lymphoma and a method of treating said brain cancers in a patient in need thereof comprising administering to the patient said compound of formula i or a pharmacologically acceptable salt thereof.. .

Combination therapies with curaxins

Provided are methods and compositions that relate to, inter alia, cbl0137 for the treatment of various cancers, optionally in combination with various agents.. .
Incuron, Llc

Compounds for the treatment of cancers associated with human papillomavirus

The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of formula (i) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of formula (i) for the treatment of cancers associated with human papillomavirus..
Piramal Enterprises Limited

Hnf4-alpha antagonist and use thereof

Provided is a hepatocyte nuclear factor 4 alpha (hnf4-α) antagonist and a use thereof. The hnf4-α antagonist selected in the present invention was confirmed to specifically bind to the ligand binding domain of hnf4-α, thereby inhibiting the activity of hnf4-α.
National Cancer Center

Lobaplatin crystal, preparation method and pharmaceutical application

The present invention relates to new crystals a, b and f of lobaplatin as well as preparation methods therefor and pharmaceutical applications thereof. Lobaplatin crystal a has a melting point tm.p.
Guizhou Yibai Pharmaceutical Company Limited

Solid oral formulation of fenretinide

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Immune mediated cancer cell destruction, systems and methods

Systems and methods for delivering electric fields to a target tissue of a patient for destruction of cancerous cells so as to elicit or induce a specific anti-cancerous cell immune response in the patient.. .
Lazure Scientific, Inc.

Portable detecting breast cancer

An apparatus for detecting abnormal masses such as breast cancer includes a measurement sensor configured to obtain a voltage at a first area of a first breast of a subject; a reference sensor configured to obtain a voltage at a second area of a second breast of the subject, a position of the first area corresponding to a position of the second area; and a detector, wherein the detector includes a differential amplifier configured to amplify a voltage input from the at least one of the measurement sensor and the reference sensor; an active low pass filter configured to pass a signal frequency of a low frequency band among signals transmitted from the differential amplifier; a driver amplifier configured to amplify a signal passed through the active low pass filter; and an analog-to-digital (ad) converter configured to convert the signal amplified by the driver amplifier into a digital signal.. .

Imaging of creatine kinase enzyme expression in cancerous tissues

The present technology is directed to apparatuses, machines and methods for determining the level of expression of creatine kinase enzyme in cancerous tissues, as well as for determining malignancy and providing a cancer prognosis. The method is based on overexpression of creatine kinase in cancer tissue and enhanced transformation of injected phosphocreatine substrate into creatine as detectable by nmr..
Sidra Medical And Research Center

Monoclonal antibodies that specifically block biological activity of a tumor antigen

This invention relates to novel monoclonal antibodies that specifically bind to the alpha-folate receptor. In some embodiments, the antibodies inhibit a biological activity of folate receptor-α (fr-α).
Morphotek, Inc.

Methods for diagnosis and prognosis of cancer

We have discovered a protein in humans, herein referred to as collagen like gene (clg) product (seq id nos: 12 and 13), that is expressed in human prostate cancer and breast cancer cell lines but not in normal adult, placenta, lung, liver, skeletal muscle, kidney or pancreas tissues. We have also discovered that the level of clg mrna expression correlates positively with the metastatic potential of the cancer cell lines tested..
Children's Medical Center Corporation

Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, pin (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (bph); a method to combine immunofluorescence and fish (if-fish) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.. .
Abbott Molecular Inc.

Antibody-based arrays for detecting multiple signal transducers in rare circulating cells

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.. .
Nestec S.a.

P13k-mtorc1-s6k1 signaling pathway biomarkers predictive of anti-cancer responses

The present invention is based, in part, on the identification of novel fi.3k-mtorci-s6k 1 signaling pathway biomarkers predictive of responsiveness to anti-cancer therapies.. .
Dana-farber Cancer Institute, Inc.

Determining risk of prostate tumor aggressiveness

This disclosure relates to methods, computer products, computer-implemented methods, and systems for predicting the probability or risk of prostate cancer recurrence and tumor aggressiveness in a patient. The method is based, in part, on the patient's risk profile that includes the presence/degree of specific copy number variations and predictive clinical factors.
The Regents Of The University Of California

Methods and kits for the prognosis and treatment of prostate cancer

Provided herein are methods for the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient the prognosis of prostate cancer progression in a patient by analyzing the gene expression in a tumor sample obtained from the patient. In particular, gene expression levels of gcom1, mex3d, trpm4, atpaf1, ptrf, glyatl1, flna, obscn, stra13, whscl, arfgap3, kdm2a, fam83h, cldn7, cnot6, and b3gnt9 are measured.
Washington State University

Aptamer targeting mage-a3 peptide and uses thereof

Disclosed herein is an aptamer targeting a mhc-presented peptide and its uses thereof. The mhc-presented peptide is expressed in various cancer cells; therefor, the aptamer of the disclosure is useful as a bio-tool to label and/or treat peptide-presenting cancer cells.
Academia Sinica

Pharmaceutical compositions comprising rna and use for treating cancer

Methods are provided for making an rna molecule derived from non-coding chimeric mitochondrial rnas (ncmtrnas), in particular antisense non-coding chimeric mitochondrial rnas (asncmtrnas), compositions containing the isolated rna molecule, methods of causing apoptosis in a cancer cell by contacting the cell with the rna molecule, and methods of treating cancers by administering the rna molecule to a subject in need thereof.. .
Andes Biotechnologies S.a.

System and cold atmospheric plasma treatment on cancer stem cells

A method for treating cancer stem cells with cold atmospheric plasma using a cold atmospheric plasma system the method comprises the steps of placing an exit port of a cold plasma delivery device 5 cm or less from target cancer stem cells, flowing the inert gas from the source through the housing at a flow rate of 5-10 ml/minute, applying electrosurgical energy of 2-5 kv at a frequency of 20-35 khz to at least one of the central electrode and the ring electrode to produce a cold plasma jet from the exit port, directing the cold plasma jet onto the target cancer stem cells, and applying the cold plasma jet onto the target cancer stem cells for at least 2 minutes. In a preferred embodiment the inert gas is helium..
U.s. Patent Innovations, Llc

Method for making and using cold atmomsphereic plasma stimulated media for cancer treatment

A method for preparing cold atmospheric plasma stimulated cell culture media with a cold atmospheric plasma system having a delivery port out of which an inert gas flows. The inert gas may be helium.
U.s. Patent Innovations, Llc

Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a bcma monoclonal antibody, conferring specific immunity against bcma positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas, multiple myeloma and leukemia..
Cellectis

Methods of inhibiting pathological angiogenesis with doppel-targeting molecules

Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (pah), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described..
Pharsogen

Cd123 specific chimeric antigen receptors for cancer immunotherapy

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from a cd123 monoclonal antibody, conferring specific immunity against cd123 positive cells. The engineered immune cells endowed with such cars are particularly suited for treating lymphomas and leukemia..
Cellectis

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Histone demethylase inhibitors

The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds.
Celgene Quanticel Research, Inc.

Form a of mesylate for nicotinamide derivatives and preparation method and application thereof

The invention discloses a form a of mesylate for nicotinamide derivatives and preparation method and application thereof, wherein the xrpd pattern of the form a of mesylate for nicotinamide derivatives has a diffraction peak at 2θ=5.34, 10.341, 14.438, 15.841, 17.32, 18.301, 18.68, 19.005, 19.577, 20.26, 21.161, 21.859, 22.379, 23.04, 23.5, 24.177, 24.959, 25.881, 26.641, 27.18, 28.3, 28.999, 29.501, 31.96, 32.258, 33.999, 36.798, 37.38 and 41.297 with the error range of the 2θ values being ±0.2. The form a of mesylate for nicotinamide derivatives provided by the present invention has excellent high-temperature stability, high-humidity stability and illumination stability, and it can be applied to drugs for treating advanced non-small cell lung cancers, gastric cancers, liver cancer or breast cancer.
Shanghai Suntrong Biotechnology Co., Ltd.

Thermal accelerant compositions and methods of use

A thermal accelerant is delivered to a tissue site and localized to modulate the shape, extent or other characteristic of rf or microwave-induced hyperthermic tissue ablation. The accelerant may be provided via an image-guided hand piece or via a lumen added to a microwave antenna, and promotes faster heating, more complete ablation and/or a more extensive treatment region to reduce recurrence of treated cancers, overcoming natural limitations, variations in tissue response and drop-off or thermal loss away from the antenna.
Brown University

Antigen binding proteins that bind pd-l1

There is disclosed compositions and methods relating to or derived from anti-pd-l1 antibodies. More specifically, there is disclosed fully human antibodies that bind pd-l1, pd-l1-binding fragments and derivatives of such antibodies, and pd-l1-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.

Cancer therapy

Provided herein is technology relating to cancer treatment and prevention and particularly, but not exclusively, to compositions and methods related to therapies for prostate cancer.. .
Madison Vaccines Inc.

In situ antigen-generating cancer vaccine

The invention provides compositions and methods for utilizing scaffolds in cancer vaccines.. .
President And Fellows Of Harvard College

Breast and ovarian cancer vaccines

The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids.
University Of Washington Through Its Center For Commercialization

Methods and compositions related to glucocorticoid receptor antagonists and breast cancer

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound..
The University Of Chicago

Novel therapeutics for brain cancer

Provided herein are novel compositions and methods to inhibit olig2 activity. The olig2 inhibitors and methods of using the same are useful, inter alia, for treating cancer.
The Regents Of The University Of California

Therapeutic compounds

And salts thereof, as well as pharmaceutical compositions comprising such compounds. The compounds are useful for treating cancers and alzheimer's disease..

Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumors

This invention directed to methods for treating select rb-positive cancers and other rb-positive abnormal cellular proliferative disorders using cdk4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select rb-positive cancers are disclosed using specific cdk4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, pd-1 inhibitor, or bcl-2 inhibitor, or combination thereof..
G1 Therapeutics, Inc.

Compounds and anti-tumor nqo1 substrates

Compositions comprising formula (i) can be selectively lethal toward a variety of different cancer cell types. The compositions are useful for the management, treatment, control, or adjunct treatment of diseases, where the selective lethality is beneficial in chemotherapeutic therapy..
The Board Of Regents Of The University Of Texas System

Bromodomain and extra-terminal protein inhibitor combination therapy

The present disclosure relates generally to compositions and methods of treating cancers, such as glioblastoma and non-hodgkin's lymphomas, or other cancers in which the subject suffers from an advanced solid tumor, comprising the administration of a bromodomain and extra-terminal protein (bet) inhibitor and at least one chemotherapeutic agent, which does not inhibit bet directly. The bet inhibitor/chemotherapeutic agent combination therapy can yield synergistic effects, thereby increasing the effectiveness of the cancer treatment as compared to the administration of either the bet inhibitor or the chemotherapeutic agent alone..
Celgene Quanticel Research, Inc.

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.. .
Jenrin Discovery

Modulators of gtpases and their use

The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the ras-homologous (rho) family of small gtpases (e.g. Rac, cdc42 and rho gtpases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-b cell lymphoma, where these gtpases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of rho gtpases plays a pivotal role (menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type i), huntington's disease and alzheimer's disease) which are mediated through these proteins.
Stc.unm

Novel sesquiterpene derivatives and their use in inflammation or cancer treatment

A new class of sesquiterpene derivative useful for treating cancerous and inflammatory diseases are disclosed. These deoxyelephantopin derivatives are effective in suppressing proliferation, migration, mobility, invasion, growth, and/or metastasis of cancer cells in a patient, or useful for enhancing an anti-proliferative effect of another anti-cancer drug on cancer cells when treating a patient, or for sensitizing and/or enhancing an anti-cancer effect of a gluthathione synthesis blocker on inhibition of triple negative breast cancer cell activity, or for treatment and/or prophylaxis of lipopolysaccharide-stimulated inflammatory response in a patient, or for all of the above.
Academia Sinica

Methods for the treatment of bladder cancer

Methods of treating bladder cancer using adapalene are disclosed herein. Adapalene can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment..
Cipla Limited

Exo-s-mecamylamine formulation and use in treatment

A pharmaceutical composition includes a therapeutically effective amount of exo-s-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-r-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg.
University Of South Florida

Automated cancer detection using mri

Methods and systems for diagnosing cancer in the prostate and other organs are disclosed. Exemplary methods comprises extracting texture information from mri imaging data for a target organ, sometimes using two or more different imaging modalities.

Method for detecting or monitoring prostate cancer

The present invention provides methods identifying subjects having prostate cancer (pca) by detecting in microparticles a pair of biomarkers. The methods disclosed can be used to distinguish subjects having pca from those having non-malignant prostate pathologies, including benign prostatic hyperplasia.
Oncosense Inc. (usa)

Protein biomarker profiles for detecting colorectal tumors

Disclosed herein are panels related to the diagnosis or recognition of colon and colorectal cancer in a subject. The disclosed panels and related methods are used to predict or assess colon tumor status in a patient.
Applied Proteomics, Inc.

Methods and compositions for evaluating breast cancer patients

Embodiments are directed to methods of evaluating the prognosis of a breast cancer patient by assessing the level of phosphorylation tyrosine 36 of estrogen receptor beta (erb). Certain embodiments are directed to methods for evaluating the prognosis of a cancer patient comprising contacting a breast cancer sample from a patient with stage ii or stage iii breast cancer with an antibody that binds phosphorylated tyrosine 36 of ei¾β; quantifying phosphorylation of tyrosine 36 of ei¾β; and classifying the patient as having a good prognosis if phosphorylated tyrosine 36 levels are elevated or classifying the patient as having a poor prognosis if tyrosine levels are decreased relative to a non-cancer control.
The Board Of Regents Of The University Of Texas System

Method of diagnosing and monitoring bladder cancer and melanoma

The present invention provides a method for the diagnosing and monitoring of melanoma. .

Methods (amacr)

A method of measuring α-methylacyl-coa racemase (amacr) activity in a sample is described comprising the steps of: (i) providing a sample; (ii) contacting said sample with a substrate compound that undergoes elimination of hydrogen and a leaving group catalysed by said amacr to produce a product compound having an additional carbon-carbon double bond; and (iii) measuring the amount of said leaving group and/or of said product compound and/or of unreacted substrate compound. Also provided are methods of diagnosis and medical imaging, in particular for use in diagnosing prostate cancer.
University Of Bath

Electrochemical for detecting the effect of anticancer drugs

An electrochemical method for detecting effect of an anticancer drug on cancer cells, including: culturing a plurality of cancer cells to form cultured cells, attaching the cultured cells onto an array of silicon nanowires (sinws) electrodes, measuring a first electrochemical response of the attached cells onto the array of electrodes, adding an anticancer drug to the attached cells onto the array of electrodes to form drug-treated cells, measuring a second electrochemical response of the drug-treated cells, and determining the effect of the anticancer drug on the cancer cells based on a comparison of the first and the second electrochemical responses.. .

Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer

The present invention provides a method of identifying a subject as having an increased risk of having or developing aggressive prostate cancer, comprising detecting in the subject the presence of various polymorphisms associated with an increased risk of having or developing aggressive prostate cancer.. .
The Johns Hopkins University

Distinguishing methylation levels in complex biological samples

Provided herein is a method for distinguishing an aberrant methylation level for dna from a first cell type, including steps of (a) providing a test data set that includes (i) methylation states for a plurality of sites from test genomic dna from at least one test organism, and (ii) coverage at each of the sites for detection of the methylation states; (b) providing methylation states for the plurality of sites in reference genomic dna from one or more reference individual organisms, (c) determining, for each of the sites, the methylation difference between the test genomic dna and the reference genomic dna, thereby providing a normalized methylation difference for each site; and (d) weighting the normalized methylation difference for each site by the coverage at each of the sites, thereby determining an aggregate coverage-weighted normalized methylation difference score. Also provided herein are sensitive methods for using genomic dna methylation levels to distinguish cancer cells from normal cells and to classify different cancer types according to their tissues of origin..
Illumina, Inc.

Methods and devices for predicting anthracycline treatment efficacy

The invention features methods, devices, and kits for predicting the responsiveness of a cancer patient (e.g., a breast cancer patient, such as a grade 1, 2, or 3 breast cancer patient) to anthracycline treatment by determining the expression levels of four chromosomal instability (cin) genes including hdgf, kiaa0286, rfc4, and msh6, collectively referred to as cin4. Patients that have a low cin4 score benefit from anthracycline treatment compared patients with a high cin4 score..
Ontario Institute For Cancer Research

Evaluation evaluating the likelihood of breast cancer

The invention relates to a method for evaluating the likelihood of a person having breast cancer, the method including detecting and quantifying specific micrornas in serum or plasma, the expression of which is related to the presence of a breast tumour. The invention also relates to the use of specific micrornas, the expression of which is related to the presence of a breast tumour..
Sistemas GenÓmicos, S.l.

The tgf(beta)-mir200-mig6 pathway and its use in the treatment of cancer as an indicator of resistance to egfr inhibitors

The present invention provides methods for identifying the susceptibility of a cancer cell or population of cells to treatment with epidermal growth factor (egf) tyrosine kinase inhibitors (tkis), such as erlotinib. Methods for the in vitro diagnosis of the susceptibility of a tumor in a subject to treatment with tkis and monitoring tumor susceptibility during treatment are also provided..
The Johns Hopkins University

Use of double-stranded dna in exosomes: a novel biomarker in cancer detection

The present invention is directed to methods of prognosing, treating, or managing treatment of cancer in a subject. These methods involve selecting a subject having cancer, obtaining, from the selected subject, a sample containing exosomes, recovering the exosomes from the sample, and isolating the double-stranded dna from within the exosomes.
Sloan-kettering Institute For Cancer Research

Immune gene signatures in urothelial carcinoma (uc)

This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.. .
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Retroviral vector having immune-stimulating activity

The disclosure provides vectors for treating cancers, method of producing such vectors and methods of use of the vectors.. .
Tocagen Inc.

Crispr-cas-related methods, compositions and components for cancer immunotherapy

Crispr/cas-related composition and methods for treatment of cancer, in particular by using grna molecules comprising a targeting domain which is complementary with a target domain from the fas, bid, ctla4, pdcd1, cblb, ptpn6, trac or trbc gene. In some embodiments, grnas are used with cas9 enzymes to cause a cleavage event in said genes within engineered chimeric antigen receptor (car) t cells.
Editas Medicine, Inc.

Diagnosis and treatment of cancers with microrna located in or near cancer-associated chromosomal features

Microrna genes are highly associated with chromosomal features involved in the etiology of different cancers. The perturbations in the genomic structure or chromosomal architecture of a cell caused by these cancer-associated chromosomal features can affect the expression of the mir gene(s) located in close proximity to that chromosomal feature.
Thomas Jefferson University

Composition and using mir-302 precursors as anti-cancer drugs for treating human lung cancer

This invention generally relates to a composition and method of using mam-made small rnas, such as small interfering rnas (sirna), micrornas (mirna) and their hairpin-like precursors (pre-mirna), as tumor suppressing anti-cancer drugs for treating human tumors and cancers, in particular, but not limited, for treating skin (melanoma), blood (leukemia), prostate, breast, liver and lung cancers as well as various neoplastic tumors, such as brain tumors and teratocarcinomas that contain a variety of tumorous and cancerous cells derived from all three germ layers of tissues, including ectoderm, mesoderm and endoderm. More specifically, the present invention relates to the use of mir-302-like sirna (sir-302) and/or mir-302 precursors (pre-mir-302) for developing novel medicines and therapies against a variety of human cancers, in particular lung cancers..

Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-pd-1 antibody and an anti-cd27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof..
Celldex Therapeutics, Inc

Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer

The present disclosure describes combination therapies comprising an antagonist of programmed death 1 receptor (pd-1) and a selective 4-1 bb agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express pd-l1.. .
Merck Sharp & Dohme Corp.

Monoclonal antibodies to progastrin and their uses

The present disclosure is directed to progastrin monoclonal antibodies, fragments thereof, compositions comprising progastrin monoclonal antibodies, and methods of making and using progastrin monoclonal antibodies and compositions thereof. The present disclosure is directed to methods of treating colorectal cancer with progastrin monoclonal antibodies and compositions comprising progastrin monoclonal antibodies or fragments thereof.
Centre National De La Recherche Scientifique (cnrs)

Method for treating breast cancer

Breast cancer cells lacking er protein expression, pgr protein expression and/or showing absence of her2 protein over-expression (i.e., triple-negative breast cancer cells, basal-like) can be efficiently targeted with an anti-kaag1 antibody and killed upon delivery of a therapeutic moiety. Antibodies and antigen binding fragments that specifically binds to kaag1 may thus be used for the, detection and therapeutic treatment of breast cancer cells that are negative for at least one of these markers.
Alethia Biotherapeutics Inc.

Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases

Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed.
The Johns Hopkins University

Modification of cupredoxin derived peptides and methods of use thereof

The present invention provides modified cupredoxin derived peptides with pharmacologic activity that have improved pharmacokinetic properties, and methods to use them to treat mammals suffering from various conditions related to the pharmacologic activities. Modifications of the cupredoxin derived peptides include amino acid sequence variants and structural derivations that increase the plasma half-life of the peptide, increase the specific activity of the pharmacologic activity, decrease immunogenicity, and decrease the biotransformation of the peptides.
The Board Of Trustees Of The University Of Illinois

Bromodomain-inhibiting compounds and pharmaceutical composition comprising same for preventing or treating a cancer

Provided is a novel compound having bromodomain and extra terminal domain (bet) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.. .
Kainos Medicine, Inc.

Pyrrolopyrimidine compounds, use as inhibitors of the kinase lrrk2, and methods for preparation thereof

The present disclosure is concerned with certain pyrrolopyrimidine compounds that are capable of inhibiting certain protein kinases, and especially the leucine-rich repeat kinase 2 (lrrk2) protein. Compounds of the present disclosure can be used to treat a number of disorders caused by or associated with abnormal lrrk2 kinase activity.
Southern Research Institute

Inhibitors of cyclin-dependent kinase 7 (cdk7)

The present invention provides novel compounds described herein, such as of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Syros Pharmaceuticals, Inc.

Fused quinoline compunds as pi3k, mtor inhibitors

(formula i), the present invention relates to the compounds of formula i, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with cancers associated with protein kinases, to their use as medicaments for use in the production of inhibition of mtor, pi3k reducing effects in warm-blooded animals such as humans.. .
Advenchen Pharmaceuticals, Nanjing Ltd.

Pyrazolone compounds and uses thereof

The invention disclosed herein is directed to compounds of formula i [formula should be entered here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, acute or chronic myeloid leukemia, melanoma, and other cancers. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of compound of formula i, or a pharmaceutically acceptable salt thereof.
Inception 2, Inc.

Histone demethylase inhibitors

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted 3-aminopyridine derivative compounds, substituted 3-aminopyridazine derivative compounds, and pharmaceutical compositions comprising said compounds.
Celgene Quanticel Research, Inc.

3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof

Wherein x is an oxygen atom and the like; y is —co—, —so2— and the like; r1 is an optionally-substituted c1-6 alkyl group, an optionally-substituted c1-6 alkylcarbonyl group and the like; r2 is an optionally-substituted c1-6 alkyl group, an optionally-substituted c1-6 alkoxy group, an optionally-substituted amino group, an optionally-substituted 5- to 12-membered monocyclic or polycyclic saturated heterocyclic group and the like; r3, r4, r5, and r6 are independently a hydrogen atom and the like which exhibits excellent effects in suppressing the proliferation and sphere-forming ability of cancer cells, and can be useful as an antitumor drug or cell growth inhibitor.. .

Method and system for calorimetry probe

Radiotherapy is one of the most effective treatments for cancer and its success depends critically on accurate targeting and delivery of the correct radiation dose. Accurate dosimetry is therefore essential to maintain and improve patient survival rates.
Sun Nuclear Corporation

Cancer immunotherapy compositions and methods

The present invention relates to compositions and methods for cancer immunotherapy. In particular, the present invention relates to engineered effector b cells and their use in cancer immunotherapy..
The Regents Of The University Of Michigan

Bladder cancer specific ligand peptides

The present invention is directed to bladder cancer specific ligand peptides, comprising the amino acid sequence x1dgrx5gf (seq id no: 1), and methods of their use, e.g., for imaging detection for diagnosis of bladder, tumor localization to guide transurethral resection of bladder cancer, imaging detection of bladder cancer for follow-up after the initial treatment that can replace or complement costly cystoscopy, imaging detection of metastatic bladder cancer, and targeted therapy for superficial and metastatic bladder cancer.. .
The Regents Of The University Of California

Antibody to mucin 4 (muc4) glycopeptide and uses thereof

The present invention provides: an antibody that has specificity for muc 4 having a sugar chain structure that is expressed at a high level in cancer cells; a glycopeptide that constitutes an antigen that is suitable for producing this antibody; and a new means and method for the diagnosis, prevention, and/or treatment of cancer by means of the aforementioned antibody. The present invention relates to a monoclonal antibody against a glycopeptide.
Medicinal Chemistry Pharmaceuticals, Co., Ltd.

Cytotoxic t lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a ctl response against pancreatic and other cancers..
Immunotope, Inc.

Immunomodulator for the treatment of cancerous and precancerous lesions in the epithelial tissue lining surfaces inside or outside body organs

“immunomodulator for topical treatment of malignant and premalignant lesions in the epithelial tissue lining inside and outside surfaces of the body”, the present invention provides a novel method of treatment for malignant and premalignant lesions in the epithelial tissue lining inside and outside surfaces, comprising the topical use of the immunomodulator, either alone or in association or combination with other drug and non-drug treatments and pharmaceutical compositions for its use.. .

Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Novel peptides and combination of peptides for use in immunotherapy against cll and other cancers

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer.
Immatics Biotechnologies Gmbh

Cancer vaccines and vaccination methods

Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.. .
Cedars-sinai Medical Center

Exogenous tap inhibitor armed oncolytic viruses and therapeutic uses thereof

The present invention relates to exogenous tap inhibitor armed oncolytic viruses that replicate selectively in cancer cells, evade cd8+ cytolytic t-cells, and induce the immune system to recognize tumor cells. Preferred viruses of the invention have a heterologous gene that encodes a function that affects antigen presentation by inhibiting tap.
Benevir Biopharm, Inc.

Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound

A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (il) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition.
Provectus Pharmatech, Inc.

Har-nds-derived stem cells, separating same, and use thereof

The present invention relates to hyaluronic acid-rich node and duct system (har-nds)-derived stem cells, a method for separating the same, and a use thereof and, more specifically, to node and ductal stem cells (ndscs), which are adult stem cells having an ability to differentiate into har-nds-derived neural cells, and hematopoietic stem cells having an ability to differentiate into blood cells. The present invention is capable of separating, from har-nds, adult stem cells ndscs and hematopoietic stem cells, which are not easy to obtain from bone marrow, peripheral blood and umbilical cord blood (cord blood), as an alternative source, and thus can be usefully used for treatment of brain diseases, neurological diseases, chronic infectious diseases, cancers, autoimmune diseases, organ regeneration treatments and various intractable diseases..
Eutilex Co., Ltd

Methods of treating ovarian cancer

Disclosed herein are methods of treating ovarian cancer comprising administering to a subject in need thereof an effective amount of methacycline, or a pharmaceutically acceptable salt thereof. The methacycline can be administered as part of treatment regimen, which also can include other chemo- or immune-therapies, radiation therapy, and/or surgical treatments..
Cipla Limited

Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders

Provided herein are methods and pharmaceutical compositions for the treatment of inflammatory disorders comprising filgotinib and a syk inhibitor.. .
Gilead Sciences, Inc.

Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof

Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (i):. .
Signal Pharmaceuticals, Llc

Combination therapy for cancer

The present invention provides preparation of medicaments for use in treating and methods of treating non-small cell lung cancer in a patient comprising: [5-(4-ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3h-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, or a pharmaceutically acceptable salt thereof, in combination, as further described herein, with an anti-vegfr2 antibody, preferably, ramucirumab.. .
Eli Lilly And Company

Method for detecting or treating triple negative breast cancer

A method of detecting triple negative breast cancer (tnbc) is provided. Overexpression of icam-1 is linked to an increased risk of tnbc.
Children's Medical Center Corporation





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Cancer for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Cancer with additional patents listed. Browse our RSS directory or Search for other possible listings.


1.935

file did exist - 12394

0 - 1 - 254